April 26 (Reuters) - Shares of Columbia Laboratories Inc. (CBRX.O: Quote, Profile , Research) jumped 23 percent on Thursday after it said another look at late-stage trial data suggested its progesterone gel may delay cervical shortening, a condition that may increase the risk of preterm birth.
